Search
Research
Crowding and other strong predictors of upper respiratory tract carriage of otitis media-relatedWe investigated predictors of nasopharyngeal carriage in Australian Aboriginal and non-Aboriginal children.
Research
Immunogenicity and safety of a combined Haemophilus influenzae type b-NeisseriaNeisseria meningitidis serogroups B, C, and Y cause most meningococcal disease in industrialized countries...
Research
Safety and Immunogencity of a Prototype Adjuvanted Inactivated Split-Virus Influenza A (H5N1) Vaccine in Infants and ChildrenHighly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role...
News & Events
The Kids Research Institute Australia researcher awarded support fundingA Kids Research Institute Australia researcher has been awarded $10,000 from the New Independent Researcher Infrastructure Support (NIRIS) award.
Research
Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trialIn many countries, infant vaccination with acellular pertussis (aP) vaccines has replaced use of more reactogenic whole-cell pertussis (wP) vaccines. Based on immunological and epidemiological evidence, we hypothesised that substituting the first aP dose in the routine vaccination schedule with wP vaccine might protect against IgE-mediated food allergy. We aimed to compare reactogenicity, immunogenicity, and IgE-mediated responses of a mixed wP/aP primary schedule versus the standard aP-only schedule.
Research
Anaphylactic Reactions During Bee Venom Immunotherapy in the Paediatric PopulationA retrospective study will review episodes of anaphylaxis during bee venom immunotherapy in children, any modifications made to the dosing schedule, and the subsequent outcomes over a nine-year period in Western Australia.
Research
World Society for Pediatric Infectious Diseases calls for action to ensure fair prices for vaccinesThe eradication of smallpox is considered one of the greatest achievements of humankind, thanks to vaccination. The widespread availability of childhood vaccines has substantially reduced childhood morbidity and mortality. Devastating infections, such as polio, have almost disappeared due to vaccination. In 2021, it was estimated that vaccination against ten selected pathogens will have averted 69 million deaths between 2000 and 2030. Increases in vaccine coverage and introduction of additional vaccines should reduce lifetime mortality by 72% in the 2019 birth cohort. However, access to vaccines that prevent life-threatening and disabling infectious diseases remains unequal.
Research
Erratum: Attitudes, perceptions, and experiences of Western Australians towards vaccine safety surveillance systems following COVID-19 vaccines: A qualitative descriptive study (Australian and New Zealand Journal of Public Health (2024) 48(1), (S132602002Concerns regarding adverse events following immunisation are a barrier to vaccine uptake. Health professionals use vaccine safety surveillance systems (VSSS) to monitor vaccines and inform the public of safety data. With little known about public attitudes, perceptions, and experiences with VSSS, we examined them in the context of COVID-19 vaccinations in Western Australia.
Research
Per Os to Protection – Targeting the Oral Route to Enhance Immune-mediated Protection from Disease of the Human NewbornValerie Verhasselt MD, PhD Head, Immunology and Breastfeeding 0402997617 Valerie.verhasselt@thekids.org.au Head, Immunology and Breastfeeding @
Research
Short-Term Active Safety Surveillance of the Spikevax and Nuvaxovid Priming Doses in AustraliaAustralia commenced administration of the Spikevax (Moderna mRNA-1273) COVID-19 vaccine in August 2021 and Nuvaxovid (Novavax NVX-CoV2373) in January 2022. This study describes the short-term safety profile of priming doses of the Spikevax and Nuvaxovid vaccines given between September 2021 and September 2023.